Medical Diagnostics · us
Roche respiratory test receives FDA clearance, adds pertussis and offers five panel configurations
Respiratory infections have similar symptoms, but testing may not always need to cover the same pathogens. Roche’s next-generation RP3 panel has received marketing clearance in the United States, allowing laboratories to choose testing coverage based on local disease prevalence; whether it can improve medication use and care workflows still requires clinical validation.
During peak respiratory infection periods, similar symptoms may be caused by different viruses or bacteria, putting pressure on both clinical assessment and testing capacity. Roche announced on November 2 that its cobas eplex third-generation respiratory pathogen panel (RP3) received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA), expanding pathogen coverage while giving laboratories greater flexibility in choosing testing combinations.
According to Roche’s announcement and reporting by *Clinical Lab Products*, RP3 uses a single nasopharyngeal swab specimen to detect up to 19 viral and bacterial targets simultaneously. Compared with the previous-generation RP2, the new panel adds Bordetella pertussis, the bacterium that causes whooping cough, and updates the assay designs for influenza viruses and SARS-CoV-2 to improve coverage of recently circulating strains.
Another key aspect of the product design is the availability of up to five panel configurations. With cobas eplex system software version 3.0 or higher, laboratories can select a configuration based on local disease prevalence and the populations they serve. This flexibility allows testing coverage to better match needs; public reports did not list the complete set of targets included in each of the five configurations.
For operation, Roche says hands-on preparation takes less than one minute, and the system can provide qualitative results within two hours, indicating whether a target has been detected. *Clinical Lab Products* reported the same workflow specifications. However, instrument analysis time differs from the total time from specimen collection to a patient receiving a report, which also depends on specimen transport and laboratory scheduling.
The regulatory developments need to be distinguished by generation and market. Roche noted that RP2 is available under emergency use authorization in the United States, while RP3 has now received 510(k) clearance. A report by Swiss news agency AWP, published by cash, also stated that RP3 was launched in countries accepting the CE mark in spring 2026, with this clearance representing a further regulatory authorization for the U.S. market.
Faster pathogen identification can provide additional information for clinical management and decisions about antibiotic use, but this announcement did not provide sensitivity or specificity data for individual RP3 targets, or study results directly demonstrating improved patient outcomes. The addition of pertussis and selectable configurations therefore represent clear product advances; whether they can further reduce unnecessary medication use and shorten care workflows still needs to be validated in actual use.